Truvada metabolizes differently in the vagina than in the rectum, leaving less room for error in protecting vaginal tissues from HIV.

Tivicay is included in Triumeq (dolutegravir/abacavir/lamivudine) and linked with insomnia in a small proportion of those on the HIV med.

A long-term study of women living with both viruses found a link between accelerated fibrosis progression and perimenopause.

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

This alternative to Truvada for prevention among those at high risk of HIV warrants more advanced research to determine its efficacy.

A CDC report found that despite their high overall risk of HIV, transgender individuals get tested only as often as cisgender heterosexuals.

A push to diagnose and rapidly treat HIV and other STIs as well as use of Truvada as PrEP are likely driving the trend.

Not sticking to the daily HIV medication regimen is also associated with increased health care costs.

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.